CETP and atherosclerosis: These results with torcetrapib + atorvastatin suggest that simultaneous inhibition of CETP and HMG-CoA reductase enzyme leads to an elevation of plasma HDL-C, and decrease in LDL-C and triglycerides and cholesterol but it does not arrest progression of atherosclerosis.